###begin article-title 0
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
M-CSF Signals through the MAPK/ERK Pathway via Sp1 to Induce VEGF Production and Induces Angiogenesis In Vivo
###end article-title 0
###begin p 1
Conceived and designed the experiments: JMC TDE. Performed the experiments: JMC TDE. Analyzed the data: JMC TDE. Contributed reagents/materials/analysis tools: YW NP AM CBM. Wrote the paper: JMC TDE. Intellectual contribution: RDR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 260 268 260 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 331 336 <span type="species:ncbi:9606">human</span>
M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes.
###end p 3
###begin title 4
Methodology and Results
###end title 4
###begin p 5
###xml 863 870 863 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 761 766 <span type="species:ncbi:9606">human</span>
In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Kelley1">[1]</xref>
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Junttila1">[3]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Falkenburg1">[4]</xref>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Misago1">[5]</xref>
###xml 288 291 288 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Green1">[6]</xref>
###xml 308 311 308 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Mancino1">[7]</xref>
###xml 410 413 410 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Wang1">[8]</xref>
###xml 500 503 500 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Lu1">[9]</xref>
###xml 865 868 865 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Kelley1">[1]</xref>
###xml 986 990 986 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Baran1">[10]</xref>
###xml 991 995 991 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-GobertGosse1">[13]</xref>
###xml 664 669 <span type="species:ncbi:9606">human</span>
Macrophage-Colony Stimulating Factor (M-CSF) acts on mononuclear phagocytes, stimulating proliferation, driving differentiation of monocytes to macrophages, and protecting these cells against apoptosis [1]-[3]. Many cell types, including fibroblasts [4], monocytes [5], endothelial cells [6] and tumor cells [7] secrete M-CSF. M-CSF recruits mononuclear phagocytes to sites of injury or inflammation by itself [8] or through a paracrine loop involving monocyte chemoattractant protein-1 (CCL2/MCP-1) [9]. Upon binding M-CSF, the M-CSF receptor dimerizes and elicits intrinsic tyrosine kinase activity triggering signaling pathways that induce cell survival. Using human monocytes, we previously demonstrated that M-CSF activates the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway, which induces cell survival by suppressing caspase-9 and caspase-3 activation [1]. Also, M-CSF activates the pro-survival mitogen-activated protein kinase (MAPK) pathway, including ERK, p38, and JNK [10]-[13].
###end p 9
###begin p 10
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Yu1">[14]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Besse1">[15]</xref>
###xml 618 622 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Richard1">[16]</xref>
###xml 793 800 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 800 804 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Pore1">[17]</xref>
###xml 934 938 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Milanini1">[18]</xref>
VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation [14]. During hypoxic conditions, the Hypoxia-Inducible Factor (HIF) proteins regulate VEGF production. At low oxygen levels, the HIFs are stabilized and bind promoter sites known as hypoxia regulatory elements (HREs), driving the transcription of over 20 hypoxia-inducible genes [15]. During normoxia, VEGF can be expressed from cells by hypoxia-independent mechanisms still involving the HIF apparatus. For example, ERK can phosphorylate and activate HIF-1alpha thereby increasing VEGF expression [16]. Alternatively, VEGF can be expressed in a HIF-independent fashion. In cancer cells lines, Akt activation through Sp1 increases VEGF expression and augments angiogenesis in vivo[17]. Also, activation of Raf-1 (an upstream regulator of the MEK/ERK pathway) can induce VEGF expression in hamster fibroblast cells [18].
###end p 10
###begin p 11
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-McDermott1">[19]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Scholl1">[20]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Sasaki1">[21]</xref>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Yuan1">[22]</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Gasparini1">[23]</xref>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Majer1">[24]</xref>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Gridelli1">[25]</xref>
###xml 1254 1258 1254 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Eubank1">[26]</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 1027 1032 <span type="species:ncbi:9606">human</span>
###xml 1238 1243 <span type="species:ncbi:9606">human</span>
M-CSF, mononuclear phagocytes, and VEGF are linked to poor prognosis in patients with solid tumors. For example, M-CSF is elevated in breast cancer patients with advanced disease and distant metastases compared to patients with localized tumors [19], [20]. In addition, a higher peripheral blood monocyte count is related to tumor progression and is an independent risk factor for recurrence of hepatocellular carcinoma after resection [21]. Finally, the importance of VEGF in tumor progression is well-established. In breast and lung cancer patients, VEGF expression negatively correlates with relapse-free and overall survival [22], [23]. Additionally, a monoclonal antibody against VEGF, Bevacizumab, inhibits tumor growth by blocking angiogenesis and is approved for use with chemotherapy to treat metastatic colon cancer [24] and metastatic non-small cell lung cancer [25]. Because of the critical effects of angiogenesis and VEGF on tumor growth and metastases and the clear negative prognostic role of M-CSF and VEGF in human tumors, we sought to define the biochemical mechanisms underlying M-CSF-induced VEGF production. This approach extends our previous observations that M-CSF directly induces functional VEGF production from human monocytes [26].
###end p 11
###begin p 12
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Here, we decipher the molecular mechanism of M-CSF-induced VEGF production. Further, we illustrate the in vivo ability of M-CSF to induce VEGF production and cause subsequent angiogenesis.
###end p 12
###begin title 13
Material and Methods
###end title 13
###begin title 14
Purification of peripheral blood monocytes
###end title 14
###begin p 15
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Marsh1">[27]</xref>
###xml 13 18 <span type="species:ncbi:9606">human</span>
Single donor human monocytes were isolated from leukocyte source packs obtained from the American Red Cross (Columbus, OH) as described previously [27].
###end p 15
###begin title 16
Inhibitor studies
###end title 16
###begin p 17
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocytes (10x106 cells/condition) were left untreated, treated with DMSO or methanol, the MEK/ERK inhibitor, U0126 (10 microM), the JNK inhibitor, SP600125 (10 microM), the p38 MAP kinase inhibitor, SB203580 (10 microM), the PI3K/Akt inhibitor, LY294002 (1 microM or 10 microM), the mTOR inhibitor, Rapamycin (0.1, 1, or 10 microM), or mithramycin (8, 40, and 200 nM) for 30 minutes (Calbiochem, San Diego, CA). Afterwards, the cells were stimulated with rhM-CSF (100 ng/ml) for 48 hours and the cell-free supernatants were frozen until assayed for VEGF by ELISA (R&D Systems, Minneapolis, MN).
###end p 17
###begin title 18
Western blot analysis
###end title 18
###begin p 19
Protein was harvested using Cell Lysis Buffer from Cell Signaling. Whole cells lysates were standardized using the Bio-Rad Protein Assay Kit. Western blots were performed using NuPAGE(R) 10% Bis-Tris gels, NuPAGE(R) MOPS SDS Running Buffer, and NuPAGE(R) Transfer Buffer (Invitrogen) and subsequently transferred to nitrocellulose paper and probed with the following antibodies: phosphorylated p44/p42 MAPK (Thr202/Tyr204) (#9101L, Cell Signaling) and equal loading was observed by blotting for total ERK2 (sc-154, Santa Cruz).
###end p 19
###begin title 20
Sp1 Transcription Factor Binding Assay
###end title 20
###begin p 21
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocytes were either left non-stimulated or stimulated with rhM-CSF (100 ng/ml) for 30 minutes. Nuclear lysates were isolated from the cells using the CelLytictrade mark NuCLEARtrade mark Extraction Kit (Sigma). All samples were normalized for total protein using the Bio-Rad Protein Assay Kit. The amount of Sp1 in the nuclear lysates was analyzed using the NoShifttrade mark Transcription Factor Assay Kit and NoShifttrade mark Sp1 reagents as described by the manufacturer (Novagen).
###end p 21
###begin title 22
Confocal microscopy
###end title 22
###begin p 23
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 188 192 <span type="species:ncbi:9925">goat</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
Human monocytes were left non-stimulated or stimulated with rhM-CSF (100 ng/ml) for 6 or 24 hours. Cells were fixed then permeablized with 1% Triton X-100 and subsequently blocked with 5% goat serum in PBS, incubated overnight with 1 microg/ml of either a primary antibody to human Sp1 (Upstate) or IgG control antibody (Santa Cruz). The cells were incubated with a 1:5000 dilution of Alexa 594-conjugated secondary antibody (Molecular Probes). The slides were then viewed and imaged using the Zeiss LSM 510 confocal microscope. Images were quantified using Image J software. Cells were differentiated from debris by using the phase contrast photos and only those cells displaying monocyte morphology, horseshoe-shaped nuclei, were included in the analysis.
###end p 23
###begin title 24
VEGF promoter analysis
###end title 24
###begin p 25
###xml 236 241 <span type="species:ncbi:9606">human</span>
All luciferase reporter constructs containing both wild type and mutant sequences based on the VEGF promoter were supplied by Dr. Amit Maity (University of Pennsylvania). 1 microg of each construct was transfected into freshly-isolated human monocytes using the Amaxa Nucleofector Transfection System as per the manufacturer's protocol (Amaxa). All cells were incubated in 100 ng/ml rhM-CSF for 16 hours, lysed using Promega Lysis Buffer on ice, and centrifuged to remove cell debris. 20 microl of each cell lysate was mixed with 90 microl luciferase substrate and read on the luminometer in triplicate.
###end p 25
###begin title 26
VEGF mRNA analysis
###end title 26
###begin p 27
###xml 168 172 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Eubank1">[26]</xref>
###xml 360 388 349 377 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGCCAGCACATAGGAGAGATG-3&#8242;</named-content>
###xml 411 437 400 426 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAAGGCCCACAGGGATTTTC-3&#8242;</named-content>
###xml 1182 1186 1117 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Eubank2">[28]</xref>
###xml 333 338 <span type="species:ncbi:9606">human</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
Monocyte total RNA was collected using the Absolutely RNAtrade mark RT-PCR Miniprep Kit Stratagene(R) (La Jolla, CA) for total RNA purification as previously described [26]. cDNA was synthesized using the Gibco BRL SuperScript First-Strand Synthesis System for RT-PCR Kit. Real-time polymerase chain reaction was performed using the human VEGF forward primer (5'-AGGCCAGCACATAGGAGAGATG-3'), and reverse primer (5'-CAAGGCCCACAGGGATTTTC-3'). The primers for VEGF mRNA were designed based on the human VEGF-A sequence obtained from PubMed (Genbank accession no. NM003376). Reaction conditions were as follows: 10 microl SYBR(R) Green PCR Master Mix (Applied Biosystems), 0.4 microl each forward and reverse VEGF primers (10 microM) or primers targeting GAPDH (control), 8.2 microl RNase-free water, and 1.0 microl cDNA (0.5 microg) for a total reaction of 20 microl. The real-time PCR was completed on the ABI PRISM Sequence Detector 7700 (PerkinElmer) using Sequence Detector software. Reaction conditions were as follows: 50degreesC for 2 min, 95degreesC for 10 min, and 40 cycles of 95degreesC for 15 s and 60degreesC for 1 min. Quantification was performed as previously described [28].
###end p 27
###begin title 28
In vivo Matrigeltrade mark plug assay
###end title 28
###begin p 29
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
C57BL/6 female mice purchased from Jackson Laboratories (Bar Harbor, ME) were anesthetized with isoflurane and subcutaneously injected with 0.5 ml growth factor-reduced Matrigeltrade mark matrix (Discovery Labware, Bedford, MA) supplemented with either PBS, rmVEGF (10 ng/ml), rmM-CSF (100 ng/ml), rmM-CSF (100 ng/ml)+anti-VEGF neutralizing antibody (5 microg/ml), or rmM-CSF (100 ng/ml)+isotype IgG antibody (5 microg/ml). All components added to the unpolymerized Matrigeltrade mark were allowed to incubate at 4degreesC for at least 12 hours prior to injection. After 10 days, the mice were sacrificed and the Matrigeltrade mark plugs removed, formalin-fixed, paraffin-embedded and sectioned.
###end p 29
###begin title 30
Immunohistochemistry
###end title 30
###begin p 31
###xml 169 175 <span type="species:ncbi:9986">rabbit</span>
Mononuclear phagocyte recruitment within the plugs was identified using an anti-F4/80 antibody (Serotec, MCAP497). VEGF was detected within the plugs by staining with a rabbit anti-VEGF antibody or the isotype IgG antibody (LabVision, RM-9128-R7). Endothelial cell infiltration into the plugs was determined by an anti-von Willebrand factor (vWf) antibody (Abcam, ab6994). Blood vessels within each plug are defined as complete circles of vWf(+)-stained cells. All staining was performed at the Pathology Core at The Ohio State University.
###end p 31
###begin title 32
Statistical analyses
###end title 32
###begin p 33
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistics were determined by The Ohio State University Medical Center for Biostatistics. For IHC of F4/80(+) cells and VEGF and the Sp1 binding assay, an independent samples Student's T-Test was used to assess differences between groups. An ANOVA with Tukey's post-hoc test was performed to determine differences between groups in the blood vessel counts, ELISA studies, confocal microscopy data and the VEGF promoter constructs data. For the inhibitor studies and the luciferase assays, difference in fold change over treatment was tested using a random-intercept mixed model. Fold change was log transformed for variance stabilization and a single overall p-value that tests if there is a difference between treatments was generated. All analyses were run on Stata 10.0, Stata Corporation, College Station, Texas. Groups were considered significantly different at p<0.05.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
M-CSF-induced VEGF production from monocytes occurs through a HIF-independent mechanism
###end title 35
###begin p 36
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Eubank1">[26]</xref>
###xml 747 756 747 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 747 756 747 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g001"><bold>Figure 1A</bold></xref>
###xml 1531 1540 1531 1540 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1531 1540 1531 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g001"><bold>Figure 1B</bold></xref>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
###xml 1126 1131 <span type="species:ncbi:9606">human</span>
We demonstrated M-CSF induces the production and release of biologically active VEGF from human monocytes [26]. Here, we elucidate the biochemical mechanism of this phenomenon by first investigating the role of the hypoxia-inducible factors (HIFs). During hypoxic stress, HIFs are the master regulators of VEGF and function by binding to the hypoxia regulatory element (HRE) sequence within the VEGF promoter. We utilized both wild type and mutant VEGF promoter constructs driving luciferase production. We transfected human monocytes with either the pGL3-basic empty vector, the same pGL3 construct containing a 1.5 kb portion of the wild type VEGF promoter, or a VEGF promoter construct containing a mutated HRE to prohibit HIF protein binding (Figure 1A). This assay measures luciferase production as a function of VEGF promoter activation. All cells were transfected using the Amaxa Nucleofector, stimulated with M-CSF, and subsequent luciferase production was measured at 16 hours and represented as fold-change over the luciferase production from the pGL3 empty vector. When transfecting the eGFP control construct into human monocytes, we observed an efficiency of 55.3% as analyzed by flow cytometry (data not shown). Cells expressing the VEGF wild type construct displayed a 4.5-fold increase in luciferase production compared to the pGL3-basic empty vector control (p = 0.020). Mutation in the HRE did not affect the luciferase production (p = 0.743) suggesting M-CSF-induced VEGF promoter activation is HIF-independent (Figure 1B).
###end p 36
###begin title 37
M-CSF induced VEGF production occurs through a HIF-independent mechanism.
###end title 37
###begin p 38
###xml 38 48 38 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(WT1.5 kb)</italic>
###xml 157 167 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#916;HRE)</italic>
###xml 574 584 566 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(WT1.5 kb)</italic>
###xml 588 598 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#916;HRE)</italic>
###xml 366 371 <span type="species:ncbi:9606">Human</span>
A) The 1.5 kb wild type VEGF promoter (WT1.5 kb) and the same promoter sequence containing a non-functional mutation of the hypoxia regulatory element (HRE) (DeltaHRE) were inserted into the pGL3-basic vector to create constructs that produce luciferase upon VEGF promoter activation. Nucleotides changed from the original wild type sequence are designated in bold. Human monocytes were transfected with either the control empty construct (pGL3-Basic), or pGL3 containing 1 microg of each of the described VEGF promoter constructs above. B) Transfected monocytes containing (WT1.5 kb) or (DeltaHRE) were allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of fresh media containing rhM-CSF (100 ng/ml) for 16 hours. The adherent cells were lysed and assayed for luciferase production using a luminometer. This data represents the mean+/-SEM of six individual blood donors. All data is represented as the fold change in luciferase over the pGL3 control construct.
###end p 38
###begin title 39
ERK plays a regulatory role in M-CSF-induced VEGF production
###end title 39
###begin p 40
###xml 48 51 48 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Kelley1">[1]</xref>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Bhatt1">[29]</xref>
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Wang2">[30]</xref>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Smith1">[31]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Berra1">[32]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Li1">[33]</xref>
###xml 943 952 935 944 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 943 952 935 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g002"><bold>Figure 2A</bold></xref>
###xml 1200 1209 1184 1193 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 1200 1209 1184 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g002"><bold>Figure 2B</bold></xref>
###xml 1317 1326 1301 1310 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1317 1326 1301 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g002"><bold>Figure 2C</bold></xref>
###xml 379 384 <span type="species:ncbi:9606">human</span>
M-CSF activates both the PI3 kinase/Akt pathway [1] and MAP kinase pathway, including ERK [29], p38 [30], and JNK [31]. Both over-expression of Akt and activation of ERK can drive VEGF production in cancer cell lines or in hamster fibroblasts, respectively [32], [33]. Therefore, we investigated the roles of Akt and the MAP kinases in M-CSF-induced VEGF production from primary human monocytes. We treated peripheral blood monocytes with pharmacological inhibitors targeting PI3 kinase, the upstream activator of Akt (LY294002), mTOR, a signaling molecule downstream of Akt (Rapamycin), JNK (SP600125), p38 (SB203580), or ERK (U0126) and stimulated these cells with M-CSF. We analyzed VEGF levels in the supernatants by ELISA. Our data suggested that the PI3-K/Akt pathway did not regulate M-CSF-induced VEGF production as neither LY294002 nor Rapamycin affected VEGF production (p = 0.898 for 1 microM and p = 0.334 for 10 microM LY294002) (Figure 2A) and (p = 1.0 for 1 microM and p = 0.640 for 10 microM Rapamycin) (data not shown). Importantly, the inhibition of ERK activity by U0126 reduced VEGF production from M-CSF-stimulated monocytes to that produced from non-stimulated cells (p<0.001) (Figure 2B). Western blot analysis confirmed that M-CSF induced ERK1/2 phosphorylation, which was inhibited by U0126 (Figure 2C). Our data also indicated that M-CSF-induced VEGF was not regulated by either p38 or JNK as inhibitors targeting these pathways did not affect M-CSF-induced VEGF production (p = 0.44 and p = 0.62, respectively) (data not shown). Cell viability in response to all inhibitors was analyzed by Trypan blue exclusion and was not adversely affected (data not shown).
###end p 40
###begin title 41
###xml 35 40 <span type="species:ncbi:9606">human</span>
M-CSF-induced VEGF production from human monocytes is blocked by ERK inhibition and mithramycin.
###end title 41
###begin p 42
###xml 181 185 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(NS)</italic>
###xml 223 230 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 267 279 259 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+DMSO)</italic>
###xml 333 336 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(1)</italic>
###xml 341 345 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(10)</italic>
###xml 659 663 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(NS)</italic>
###xml 711 723 693 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+DMSO)</italic>
###xml 763 788 745 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+U0126 (10 &#181;M))</italic>
###xml 1221 1225 1193 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(NS)</italic>
###xml 1263 1275 1235 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+DMSO)</italic>
###xml 1279 1292 1251 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+U0126)</italic>
###xml 1691 1695 1663 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(NS)</italic>
###xml 1735 1742 1707 1714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 1744 1756 1716 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+MeOH)</italic>
###xml 1758 1805 1730 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF plus 8 nM, 40 nM, or 200 nM mithramycin)</italic>
###xml 945 950 <span type="species:ncbi:9606">human</span>
A) Monocytes were pre-incubated with DMSO (vehicle control), 1 microM or 10 microM the PI3 kinase inhibitor (LY294002) for 30 minutes. The monocytes were either left non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) (M-CSF), with rhM-CSF (100 ng/ml) plus DMSO (M-CSF+DMSO), or rhM-CSF (100 ng/ml) plus 1 or 10 microM LY294002 (1) and (10) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data represent the mean+/-SEM from four independent donors. B) Monocytes were pre-incubated with DMSO (vehicle control) or 10 microM of the inhibitor of ERK activity (U0126) for 30 minutes. The monocytes were either left non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) plus DMSO (M-CSF+DMSO) or with rhM-CSF (100 ng/ml) plus U0126 (M-CSF+U0126 (10 microM)) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data represent the mean+/-SEM from six independent donors. C) Freshly-isolated human monocytes were plated overnight in 5% FBS and M-CSF (20 ng/ml). The next day the cells were starved for 2 hours in minimal media. For the last 30 minutes, DMSO (vehicle control) or 10 microM U0126 was added to the appropriate samples. The cells were left non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) (M-CSF+DMSO) or (M-CSF+U0126) for 10 minutes. Cell lysates were probed for phospho-ERK MAP Kinase (Thr202) and total ERK MAP Kinase by western blot analysis. This data is representative of two independent monocyte donors. D) Monocytes were pre-incubated with methanol (vehicle control) or 8, 40, or 200 nM of the Sp1 transcription factor binding inhibitor, mithramycin, for 45 minutes. The cells were either left non-stimulated (NS) or stimulated with rhM-CSF (100 ng/ml) (M-CSF), (M-CSF+MeOH), (M-CSF plus 8 nM, 40 nM, or 200 nM mithramycin) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data represent the mean+/-SEM from ten independent blood donors.
###end p 42
###begin title 43
Mithramycin inhibits VEGF production
###end title 43
###begin p 44
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Ramos1">[34]</xref>
###xml 115 119 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Novak1">[35]</xref>
###xml 693 702 693 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2D</bold>
###xml 693 702 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g002"><bold>Figure 2D</bold></xref>
###xml 217 222 <span type="species:ncbi:9606">human</span>
Sp1 and AP-2 are transcription factors phosphorylated and activated by ERK [34] and depicted as regulators of VEGF [35]. To investigate the regulatory role of Sp1 or AP-2 in M-CSF-induced VEGF production, we cultured human monocytes and pre-treated with methanol (vehicle control) or mithramycin, an inhibitor that intercalates into GC-rich regions of DNA and inhibits the binding of transcription factors like Sp1 and AP-2. Monocytes were left untreated or treated with M-CSF for 48 hours and VEGF levels in the supernatants were analyzed by ELISA. Mithramycin (40 nM and 200 nM) significantly inhibited M-CSF-induced VEGF production compared to vehicle-treated cells (p<0.05, respectively) (Figure 2D). Cell viability as assessed by Trypan Blue exclusion was not affected in cells treated with mithramycin up to 200 nM (data not shown).
###end p 44
###begin p 45
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
To verify whether the inhibitory effect of mithramycin was due to inhibition of Sp1 binding, we attempted to use siRNA against Sp1. Stealthtrade mark RNAi targeting Sp1 was transfected into primary human monocytes using Lipofectamine and assayed for a reduction in total Sp1 protein by Western blot. We found that protein levels of Sp1 were not depleted from these cells until 48 hours after transfection. This created a challenge in VEGF determination as cultured, primary human monocytes differentiate into macrophages which become less responsive to M-CSF and therefore make it difficult to measure VEGF production from these cells. Additionally, transfection of monocytes with Lipofectamine alone induced the production of VEGF that masked induction of VEGF by M-CSF (data not shown). As a result, we attempted to transfect the siRNA using the Amaxa Nucleofector. Using this method, transfection alone induced the production of the soluble form of VEGFR-1, which sequesters VEGF from antigenic detection by ELISA. For these reasons, we chose to perform multiple techniques described below to verify the role of Sp1 in M-CSF-induced VEGF production from these cells.
###end p 45
###begin title 46
Sp1 is a downstream activator in M-CSF-induced VEGF production
###end title 46
###begin p 47
###xml 387 396 387 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 387 396 387 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g003"><bold>Figure 3A</bold></xref>
###xml 358 363 <span type="species:ncbi:9606">human</span>
The activation of Sp1 during M-CSF stimulation has not been previously reported. To confirm that M-CSF induces Sp1 activation, we performed an Sp1 binding assay to measure levels of Sp1 translocation to the nucleus in monocytes stimulated with M-CSF for 30 minutes. Our results indicate that M-CSF increased the amount of Sp1 that migrated to the nucleus of human monocytes (p = 0.008) (Figure 3A).
###end p 47
###begin title 48
M-CSF induces Sp1 nuclear localization in an ERK-dependent manner.
###end title 48
###begin p 49
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(NS)</italic>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 733 749 727 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Non-stimulated)</italic>
###xml 786 798 780 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+DMSO)</italic>
###xml 803 816 797 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+U0126)</italic>
###xml 901 910 895 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(top row)</italic>
###xml 1039 1044 1033 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(red)</italic>
###xml 1090 1096 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(blue)</italic>
###xml 3 8 <span type="species:ncbi:9606">Human</span>
###xml 338 344 <span type="species:ncbi:9986">rabbit</span>
###xml 389 393 <span type="species:ncbi:9925">goat</span>
###xml 399 405 <span type="species:ncbi:9986">rabbit</span>
###xml 593 598 <span type="species:ncbi:9606">Human</span>
A) Human monocytes were left non-stimulated (NS) or stimulated with rhM-CSF (100 ng/ml) (M-CSF) for 30 minutes. Nuclear lysates were isolated and normalized for total protein. Sp1 that translocated into the nucleus in response to M-CSF was analyzed using a biotinylated Sp1 DNA sequence bound to a streptavidin-coated plate, a polyclonal rabbit anti-Sp1 primary antibody, a HRP-conjugated goat anti-rabbit IgG secondary antibody, and TMB substrate. The absorbance was read at 450 nm to reflect Sp1 within the nucleus. These data represent the mean+/-SEM from four independent blood donors. B) Human monocytes were starved for 6 hours, inhibited for 30 minutes with U0126 (10 microM) or DMSO (vehicle control) and left non-stimulated (Non-stimulated) or treated with rhM-CSF for 6 hours (M-CSF+DMSO) and (M-CSF+U0126). The cells were fixed, permeablized, and stained with a normal IgG control antibody (top row) or a primary antibody targeting Sp1 followed by subsequent staining with Alexa 594-conjugated secondary antibody, targeting Sp1 (red), and with DAPI stain designating the nucleus (blue). Images were captured using the Zeiss LSM 510 confocal microscope. These pictures are representative of four individual monocyte donors. C) Quantification of Sp1 localization to the nucleus of monocytes (horseshoe-shaped nuclei) using Image J software. This data represents mean+/-SEM of cells from four individual trials.
###end p 49
###begin p 50
###xml 377 386 377 386 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 377 386 377 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g003"><bold>Figure 3B</bold></xref>
###xml 666 675 666 675 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 666 675 666 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g003"><bold>Figure 3C</bold></xref>
###xml 96 101 <span type="species:ncbi:9606">human</span>
To investigate the role of Erk in Sp1 nuclear translocation, we analyzed localization of Sp1 in human monocytes by confocal microscopy. Monocytes were pre-incubated with DMSO (vehicle control) or U0126 and left untreated or treated with M-CSF for 6 or 24 hours. The cells were fixed and stained using a fluorescently-conjugated anti-Sp1 antibody and DAPI to stain the nucleus (Figure 3B). Image J software analysis confirmed that M-CSF enhanced Sp1 nuclear localization compared to untreated monocytes (p<0.001). Furthermore, the ERK inhibitor, U0126, blocked Sp1 nuclear translocation compared to cells treated with M-CSF plus the vehicle control (DMSO) (p<0.001) (Figure 3C).
###end p 50
###begin title 51
M-CSF up-regulates VEGF mRNA transcription in an ERK- and Sp1-dependent manner
###end title 51
###begin p 52
###xml 309 318 309 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</bold>
###xml 309 318 309 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g004"><bold>Figure 4A</bold></xref>
###xml 514 523 514 523 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4B</bold>
###xml 514 523 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g004"><bold>Figure 4B</bold></xref>
###xml 547 556 547 556 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4C</bold>
###xml 547 556 547 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g004"><bold>Figure 4C</bold></xref>
Next, we examined the role of Erk and Sp1 in the transcriptional regulation of VEGF mRNA. We isolated total RNA from monocytes left untreated or treated with M-CSF. Using Real-Time PCR, we found a significant increase in VEGF mRNA at 6 hours of M-CSF stimulation compared to the untreated sample (p = 0.008) (Figure 4A). Next, we isolated RNA from cells pre-incubated with U1026, mithramycin, or vehicle controls and treated with M-CSF. Real-time PCR analysis revealed that inhibiting the activity of ERK (U0126) (Figure 4B) or Sp1 (mithramycin) (Figure 4C) significantly decreased VEGF mRNA transcription (p = 0.037 and p = 0.017, respectively). These data further supports our hypothesis that M-CSF-induced VEGF production is transcriptionally regulated and is dependent on both ERK and Sp1 activity.
###end p 52
###begin title 53
M-CSF regulates VEGF mRNA transcription through ERK and Sp1.
###end title 53
###begin p 54
###xml 688 695 684 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 697 709 693 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+DMSO)</italic>
###xml 711 734 707 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+U0126 10 &#181;M)</italic>
###xml 1095 1102 1087 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 1104 1116 1096 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+MeOH)</italic>
###xml 1118 1139 1110 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+Mith (200 nM))</italic>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
A) Freshly isolated human monocytes were cultured overnight in 5% FBS and subsequently starved for 2 hours in minimal media. The cells were stimulated with 100 ng/ml rhM-CSF for 6 hours followed by isolation of RNA. cDNA was synthesized from total cellular RNA, standardized, and subjected to SYBR Green real-time PCR using primers specific for VEGF-A. The data represents the mean+/-SEM of six individual donors. B) Freshly isolated human monocytes were cultured overnight in 5% FBS and subsequently starved for 2 hrs followed by pre-treatment with either DMSO (vehicle control) or U0126 (10 microM) in minimal media for 30 minutes. The cells were then stimulated with 100 ng/ml rhM-CSF (M-CSF), (M-CSF+DMSO), (M-CSF+U0126 10 microM) and analyzed as stated in A. The data represents the mean+/-SEM of three individual donors. C) Freshly isolated human monocytes were cultured overnight in 5% FBS and subsequently starved for 2 hours followed by pre-treatment with either methanol (vehicle control) or mithramycin (200 nM) in minimal media. The cells were then stimulated with 100 ng/ml rhM-CSF (M-CSF), (M-CSF+MeOH), (M-CSF+Mith (200 nM)) and analyzed as in A. The data represents the mean+/-SEM of four individual donors.
###end p 54
###begin title 55
ERK and Sp1 are essential for M-CSF to functionally regulate the VEGF promoter
###end title 55
###begin p 56
###xml 598 607 598 607 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 598 607 598 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g005"><bold>Figure 5A</bold></xref>
###xml 1162 1171 1162 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</bold>
###xml 1162 1171 1162 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g005"><bold>Figure 5B</bold></xref>
###xml 74 79 <span type="species:ncbi:9606">human</span>
To investigate the functional role of ERK and Sp1, we transfected primary human monocytes with wild type or mutant VEGF promoter constructs that drive luciferase production when activated. The VEGF wild type promoter region (+54 to -88); the identical region of the VEGF promoter with the two Sp1 regions (-85 to -80 and -74 to -69) mutated to inactivity by replacing GC to AA in both instances resulting in no Sp1 binding; an AP-2 mutant (-80 to -73) by changing the GG at -75 and -76 to TA; and an Sp1/AP-2 double mutant were spliced into the pGL3-basic vector to create the promoter constructs (Figure 5A). To interrogate the role of ERK in the functional activity of the VEGF promoter, we transfected monocytes with the VEGF wild type construct and inhibited ERK activity with U0126 treatment. After 16 hours of M-CSF stimulation, cells transfected with the VEGF wild type construct produced 10-fold more luciferase than the pGL3 control vector. Inhibition of ERK activation by U0126 caused a statistically significant reduction in luciferase production from M-CSF-stimulated cells compared to the cells challenged with M-CSF plus vehicle control (p<0.001) (Figure 5B).
###end p 56
###begin title 57
ERK and Sp1 are necessary for M-CSF induced functional activation of the VEGF promoter.
###end title 57
###begin p 58
###xml 96 108 96 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;88/+54 WT)</italic>
###xml 169 177 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Sp1</italic>
###xml 186 195 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;AP-2</italic>
###xml 228 246 220 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Sp1/&#916;AP-2</italic>
###xml 483 495 467 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;88/+54 WT)</italic>
###xml 589 607 569 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;88/+54 WT+U0126)</italic>
###xml 905 917 885 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;88/+54 WT)</italic>
###xml 919 929 899 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#916;Sp1)</italic>
###xml 931 942 907 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#916;AP-2)</italic>
###xml 947 967 919 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#916;Sp1/&#916;AP-2)</italic>
A) The wild type VEGF promoter (region -88 to +54 relative to the transcription start site (0)) (-88/+54 WT) and the same promoter sequence containing mutations of Sp1 (DeltaSp1), AP-2 (DeltaAP-2), and a Sp1/AP-2 double mutant (DeltaSp1/DeltaAP-2) were inserted into the pGL3-basic vector to drive luciferase production upon VEGF promoter activation. Nucleotides changed in the mutated sequences are designated in bold. B) Transfected monocytes containing the pGL3 control vector or (-88/+54 WT) were allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of 10 microM U0126 (-88/+54 WT+U0126) for 30 minutes. The cells were washed and fresh media containing rhM-CSF (100 ng/ml) was added for 16 hours, when the cells were lysed and assayed for luciferase production using a luminometer. This data represents the mean+/-SD of six individual blood donors. C) Transfected monocytes containing (-88/+54 WT), (DeltaSp1), (DeltaAP-2), or (DeltaSp1/DeltaAP-2) were allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of fresh media containing rhM-CSF (100 ng/ml). After 16 hours, adherent cells were lysed and assayed for luciferase production using a luminometer. This data represents the mean+/-SD of three individual blood donors.
###end p 58
###begin p 59
###xml 633 642 633 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</bold>
###xml 633 642 633 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g005"><bold>Figure 5C</bold></xref>
Next, the VEGF mutant constructs were utilized to investigate the role of AP-2 in this system and to confirm the biological activity of Sp1 in response to M-CSF. Again, M-CSF induced a significant 10-fold increase in luciferase production from monocytes transfected with the VEGF wild type construct compared to cells transfected with the control pGL3 empty vector (p<0.001). Monocytes transfected with the Sp1 mutant or the Sp1/AP-2 double mutant produced levels of luciferase similar to cells transfected with the empty vector and significantly less than the cells transfected with the VEGF wild type construct (p<0.001 for both) (Figure 5C). Furthermore, the role of AP-2 in this system was minimal, as there was not a statistically significant reduction in luciferase produced by cells transfected with the AP-2 mutant construct compared to the wild type construct (p = 0.105). These data solidify our hypothesis that M-CSF induces VEGF production through the MAPK/ERK pathway via Sp1.
###end p 59
###begin title 60
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
M-CSF promotes mononuclear phagocyte recruitment, induces VEGF production, and enhances angiogenesis in vivo
###end title 60
###begin p 61
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 598 607 589 598 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 598 607 589 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g006"><bold>Figure 6A</bold></xref>
###xml 738 747 729 738 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 738 747 729 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g006"><bold>Figure 6B</bold></xref>
###xml 1171 1180 1162 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A</bold>
###xml 1171 1180 1162 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g007"><bold>Figure 7A</bold></xref>
###xml 1320 1329 1311 1320 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7B</bold>
###xml 1320 1329 1311 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g007"><bold>Figure 7B</bold></xref>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
###xml 844 850 <span type="species:ncbi:10090">murine</span>
With the molecular mechanism of M-CSF-induced VEGF production established, we next investigated the in vivo role of VEGF induced by M-CSF. We performed an in vivo angiogenesis assay by mixing PBS, VEGF or M-CSF with Matrigeltrade mark and subcutaneously injected the solution into the flanks of C57Bl/6 female mice. After 10 days, the plugs were removed and fixed for analysis by immunohistochemistry. First, we confirmed the ability of M-CSF to recruit mononuclear phagocytes by staining the PBS- and M-CSF-containing plugs with an antibody specific for F4/80, a marker of mononuclear phagocytes (Figure 6A). Significantly more F4/80(+) cells were present in the M-CSF-treated plugs compared to those plugs treated with PBS (p = 0.046) (Figure 6B). Next, we stained plugs containing PBS, VEGF (positive control), or M-CSF with an antibody for murine VEGF to investigate if the presence of M-CSF in the Matrigel plug augmented VEGF levels. Qualitatively, more VEGF was present in the M-CSF plugs compared to the PBS plugs. Additionally, the control stains demonstrate the specificity of the VEGF antibody as staining with IgG isotype antibody produced no positive areas (Figure 7A). Quantitatively, M-CSF significantly elevated the amount of VEGF (brown stain) in the plugs compared to those plugs with PBS (p = 0.026) (Figure 7B).
###end p 61
###begin title 62
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
M-CSF induces mononuclear phagocyte recruitment in vivo.
###end title 62
###begin p 63
###xml 47 52 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PBS)</italic>
###xml 76 83 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 179 186 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 441 447 417 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(left)</italic>
###xml 570 577 546 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(right)</italic>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
A) Matrigeltrade mark was resuspended with PBS (PBS) or rmM-CSF (100 ng/ml) (M-CSF) at 4degreesC overnight and then injected subcutaneously into mice. Matrigeltrade mark was left in situ for 10 days and then harvested. The plugs were stained for mononuclear phagocytes using an anti-mouse F4/80 antibody. Brown staining represents F4/80(+) cells within the plug. Pictures shown were taken using a dissecting microscope (1.5x objective lens) (left) to display overall mononuclear phagocyte influx between conditions as well as an inverted microscope (20x objective lens) (right) to show detailed staining of these cells. B) The percent of F4/80(+) cells (brown stain) per plug was evaluated from 15 digital images captured randomly in a blinded manner. Adobe Photoshop histogram pixel analysis of the brown stain was used for quantification. This data represents three plugs per group.
###end p 63
###begin title 64
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
M-CSF induces VEGF and regulates angiogenesis in vivo.
###end title 64
###begin p 65
###xml 47 52 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PBS)</italic>
###xml 72 78 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VEGF)</italic>
###xml 102 109 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 610 615 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PBS)</italic>
###xml 635 641 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VEGF)</italic>
###xml 663 670 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF)</italic>
###xml 741 774 719 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(M-CSF+anti-VEGF neutralizing Ab)</italic>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
###xml 835 840 <span type="species:ncbi:10090">mouse</span>
A) Matrigeltrade mark was resuspended with PBS (PBS), rmVEGF (10 ng/ml) (VEGF) or rmM-CSF (100 ng/ml) (M-CSF). The slides were stained with either an anti-mouse VEGF antibody or its isotype IgG. Brown staining represents VEGF within the plug. Pictures were taken using a 20x objective lens. B) The amount of brown stain (VEGF) within the plugs was determined by taking 15 digital images randomly using a 20x objective lens in a blinded manner. Quantification of VEGF within each plug was determined by Adobe Photoshop histogram pixel analysis of the brown stain. C) Matrigeltrade mark was resuspended with PBS (PBS), rmVEGF (10 ng/ml) (VEGF), rmM-CSF (100 ng/ml) (M-CSF), or rmM-CSF (100 ng/ml)+anti-VEGF neutralizing antibody (5 microg/ml) (M-CSF+anti-VEGF neutralizing Ab). The plugs were stained for endothelial cells using an anti-mouse von Willebrand factor (vWf) antibody. Brown staining represents vWf(+) cells within the plugs. Pictures were taken using a 20x objective lens. D) Quantification of blood vessels within each plug was determined by counting the total number of vWf(+)-stained endothelial cells that formed a complete circle (red arrows) throughout each entire plug using a 20x objective lens in a blinded manner. This data represents three plugs per group.
###end p 65
###begin p 66
###xml 547 556 538 547 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7C</bold>
###xml 547 556 538 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g007"><bold>Figure 7C</bold></xref>
###xml 959 968 950 959 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7D</bold>
###xml 959 968 950 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003405-g007"><bold>Figure 7D</bold></xref>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
To investigate the angiogenic potential of VEGF produced by M-CSF within these plugs, we mixed PBS, VEGF, M-CSF, M-CSF plus an anti-VEGF neutralizing antibody, or M-CSF plus an isotype IgG antibody into Matrigeltrade mark and injected into the flanks of mice. We analyzed blood vessel formation in the plugs by staining for von Willebrand factor (vWf), a glycoprotein present in blood plasma and produced by endothelial cells, and counted the number of vWf-positive cells lining blood vessel lumens (completely-lined circles) throughout the plug (Figure 7C). We found significant increases in blood vessels in plugs containing either VEGF or M-CSF compared to plugs containing PBS (p = 0.042 and p = 0.006, respectively). Furthermore, the number of blood vessels in plugs containing M-CSF plus a VEGF neutralizing antibody were significantly less than M-CSF-containing plugs and no different than PBS-containing plugs (p = 0.009 and p = 0.970, respectively) (Figure 7D). We observed no difference in blood vessel presence between plugs containing M-CSF and plugs containing M-CSF plus an isotype antibody (data not shown). These data solidify M-CSF-induced recruitment of mononuclear phagocytes and production of VEGF as an angiogenesis-inducing phenomenon.
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Eubank1">[26]</xref>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Varney1">[36]</xref>
###xml 767 774 767 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:9606">human</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
We previously reported that human monocytes produce biologically-active VEGF in response to M-CSF stimulation [26]. This observation has been subsequently confirmed by Varney et al [36]. Here, we first investigated the molecular mechanisms involved in M-CSF-induced VEGF production from human monocytes. We provide data to support the hypothesis that M-CSF-induced VEGF production from human monocytes is mediated by ERK activation leading to the activation of Sp1. We found activated Sp1 translocated to the nucleus, binds to and induces VEGF promoter activation and results in VEGF production. Additionally, we found no role of the hypoxia inducible factors (HIFs) in this mechanism. Furthermore, for the first time, we demonstrate the angiogenic activity of M-CSF in vivo and illustrate that VEGF is the key molecule causing M-CSF-induced angiogenesis.
###end p 68
###begin p 69
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Okazaki1">[37]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Ramos1">[34]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Pages1">[38]</xref>
###xml 98 104 <span type="species:ncbi:10090">murine</span>
###xml 656 661 <span type="species:ncbi:9606">human</span>
M-CSF can activate multiple cell signaling pathways that lead to VEGF production. For example, in murine cardiomyocytes, M-CSF functions through Akt to produce VEGF in response to ischemic injury, improving cardiac function [37]. Also, M-CSF activates the MAP kinases which play roles in VEGF production as ERK activation enhances VEGF promoter activity and p38 and JNK stabilize VEGF mRNA [34]. Using pharmacological inhibitors of PI3 kinase and mTOR, a downstream molecule in the Akt pathway, we found no role for the PI3 kinase/Akt pathway in M-CSF-induced VEGF production. Also, inhibition of p38 or JNK did not affect M-CSF induced VEGF production in human monocytes. However, it is possible that p38 and JNK can functionally compensate for each other as they have been shown to have the same mechanism of increasing VEGF levels by stabilizing VEGF mRNA [38].
###end p 69
###begin p 70
###xml 179 183 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Richard1">[16]</xref>
###xml 185 189 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-MilaniniMongiat1">[39]</xref>
###xml 432 436 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Dery1">[40]</xref>
###xml 620 624 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Varney1">[36]</xref>
The VEGF promoter contains binding sites for the transcription factors Sp1, AP-2 and the HIFs. Interestingly, ERK can induce the direct phosphorylation of both HIF-1alpha and Sp1 [16], [39]. The HIFs are known as the master regulators of VEGF and are responsible for the production of VEGF in response to hypoxia. However, HIFs can also induce VEGF production in non-hypoxic environments in response to cytokines and growth factors [40]. Varney et al demonstrated enhanced levels of HIF-1alpha after 72 hours of M-CSF stimulation and showed M-CSF-induced binding to the HRE by EMSA, suggesting a HIF-dependent mechanism [36]. However, when we mutated the HRE within the VEGF promoter, we did not observe any reduction in the levels of VEGF promoter activity in response to M-CSF. M-CSF may affect the stability of the HIFs and induce their binding to the HRE, but we did not observe a functional role for HIF binding in M-CSF-induced VEGF promoter activity.
###end p 70
###begin p 71
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Milanini1">[18]</xref>
###xml 984 989 <span type="species:ncbi:9606">human</span>
The transcription factor Sp1 is activated by ERK and induces VEGF production in other cells. Milanini et al demonstrated a cooperative effect of AP-2 and Sp1 to activate the VEGF promoter. They transfected a fibroblast cell line with mutated VEGF promoter constructs and found that only the VEGF promoter construct with mutations in both the Sp1 and AP-2 binding sites displayed reduced promoter activation [18]. By performing similar promoter assay experiments, we found that a mutation in the Sp1 binding site alone was sufficient to reduce M-CSF-induced VEGF promoter activity to basal levels. Mutation of the AP-2 binding site within the VEGF promoter construct did reduce luciferase levels about 20%, however, this reduction was not statistically significant or comparable to the luciferase production observed with the Sp1 mutant. Therefore, we do not rule out a possible cooperative effect of Sp1 and AP-2 for VEGF promoter activation, but in our model of M-CSF stimulation of human monocytes, we found Sp1 to be the main transcription factor responsible for VEGF production.
###end p 71
###begin p 72
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Baran1">[10]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Leonard1">[41]</xref>
###xml 647 654 647 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 806 810 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Pages1">[38]</xref>
###xml 821 825 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003405-Tojo1">[43]</xref>
Finally, we demonstrate the ability of M-CSF to induce angiogenesis in vivo. Using the Matrigel plug angiogenesis assay, we showed that M-CSF recruited mononuclear phagocytes, increased VEGF protein levels, and increased the number of blood vessels formed within the Matrigel plug. The recruitment of F480-positive cells was expected as M-CSF is a known chemoattractant for monocytes/macrophages, alone or through induction of monocyte chemoattractant protein (CCL2/MCP-1) by monocytes [10], [41]. Our observation of increased VEGF production and angiogenesis within the M-CSF-containing plugs confirms the ability of M-CSF to induce angiogenesis in vivo. In addition to inducing VEGF production from monocytes, M-CSF is also known to stimulate the production of other pro-angiogenic factors, such as IL-8 [38] and MMP-9 [43]. To decipher the angiogenic molecule responsible for the blood vessel formation in the M-CSF-containing plugs, we added a neutralizing antibody to VEGF to the M-CSF-containing plugs. The neutralization of VEGF within these plugs significantly reduced the angiogenesis implicating VEGF as a necessary molecule in M-CSF-induced angiogenesis.
###end p 72
###begin p 73
###xml 677 684 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 464 469 <span type="species:ncbi:9606">human</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
In summary, we demonstrate the biochemical details of M-CSF-induced VEGF production. We propose a pathway involving M-CSF-induced ERK activation followed by ERK-induced phosphorylation of the transcription factor Sp1, which then translocates to the nucleus and binds to its specific sequence within the VEGF promoter to drive transcription of VEGF mRNA. Previous data on VEGF regulation has been obtained using cell lines; we demonstrate our phenomenon in primary human monocytes, enhancing the relevance of this observation. This manuscript describes the pro-angiogenic potential of M-CSF as it pertains to mononuclear phagocyte recruitment, VEGF production, and angiogenesis in vivo. The abundance of clinical data from cancer patients correlating high levels of M-CSF, mononuclear phagocytes, and VEGF with poor prognosis highlights the importance of increasing our understanding of this paradigm. We believe studies linking these three components may cultivate understanding and aid in the genesis of novel therapies for numerous cancers.
###end p 73
###begin p 74
We would like to thank Dr. Susheela Tridandapani for her assistance in preparing this manuscript. We also thank Susie Jones and The Ohio State University Pathology Core Facility for performing immunohistochemistry. We thank Gary Phillips and The Ohio State University Center for Biostatistics for statistical contribution.
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
Macrophage colony-stimulating factor promotes cell survival through Akt/protein kinase B.
###end article-title 76
###begin article-title 77
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Activation and proliferation signals in murine macrophages: Stimulation of glucose uptake by hemopoietic growth factors and other agents.
###end article-title 77
###begin article-title 78
M-CSF induced differentiation of myeloid precursor cells involves activation of PKC-delta and expression of pkare.
###end article-title 78
###begin article-title 79
Gene-expression and release of macrophage-colony stimulating factor in quiescent and proliferating fibroblasts. effects of serum, fibroblast growth-promoting factors, and IL-1.
###end article-title 79
###begin article-title 80
###xml 49 54 <span type="species:ncbi:9606">human</span>
Enhancing effects of IL-2 on M-CSF production by human peripheral blood monocytes.
###end article-title 80
###begin article-title 81
A comparison of macrophage colony-stimulating factor (M-CSF) gene expression in primary and immortalized endothelial cells.
###end article-title 81
###begin article-title 82
Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
###end article-title 82
###begin article-title 83
Induction of monocyte migration by recombinant macrophage colony-stimulating factor.
###end article-title 83
###begin article-title 84
Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.
###end article-title 84
###begin article-title 85
The role of ROS and RNS in regulating life and death of blood monocytes.
###end article-title 85
###begin article-title 86
The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase.
###end article-title 86
###begin article-title 87
The JNK are important for development and survival of macrophages.
###end article-title 87
###begin article-title 88
M-CSF stimulated differentiation requires persistent MEK activity and MAPK phosphorylation independent of Grb2-sos association and phosphatidylinositol 3-kinase activity.
###end article-title 88
###begin article-title 89
###xml 96 101 <span type="species:ncbi:9606">human</span>
MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor.
###end article-title 89
###begin article-title 90
###xml 96 101 <span type="species:ncbi:9606">human</span>
Effect of cytokines and growth factors on the macrophage colony-stimulating factor secretion by human bone marrow stromal cells.
###end article-title 90
###begin article-title 91
p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.
###end article-title 91
###begin article-title 92
Sp1 is involved in akt-mediated induction of VEGF expression through an HIF-1-independent mechanism.
###end article-title 92
###begin article-title 93
p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts.
###end article-title 93
###begin article-title 94
Circulating macrophage colony stimulating factor as a marker of tumour progression.
###end article-title 94
###begin article-title 95
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study.
###end article-title 95
###begin article-title 96
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma.
###end article-title 96
###begin article-title 97
###xml 96 103 <span type="species:ncbi:9606">patient</span>
Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer.
###end article-title 97
###begin article-title 98
Prognostic value of vascular endothelial growth factor in breast cancer.
###end article-title 98
###begin article-title 99
Oncologists' current opinion on the treatment of colon carcinoma.
###end article-title 99
###begin article-title 100
The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments.
###end article-title 100
###begin article-title 101
###xml 89 94 <span type="species:ncbi:9606">human</span>
M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes.
###end article-title 101
###begin article-title 102
Regulation of monocyte survival in vitro by deposited IgG: Role of macrophage colony-stimulating factor.
###end article-title 102
###begin article-title 103
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.
###end article-title 103
###begin article-title 104
###xml 160 165 <span type="species:ncbi:9606">human</span>
Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes.
###end article-title 104
###begin article-title 105
###xml 71 76 <span type="species:ncbi:9606">human</span>
The role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival.
###end article-title 105
###begin article-title 106
###xml 130 134 <span type="species:ncbi:10090">mice</span>
ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice.
###end article-title 106
###begin article-title 107
MAP kinases and hypoxia in the control of VEGF expression.
###end article-title 107
###begin article-title 108
A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells.
###end article-title 108
###begin article-title 109
Induction of MMP-10 and MMP-1 in a squamous cell carcinoma cell line by ultraviolet radiation.
###end article-title 109
###begin article-title 110
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor.
###end article-title 110
###begin article-title 111
Paracrine regulation of vascular endothelial growth factor-a expression during macrophage-melanoma cell interaction: Role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor.
###end article-title 111
###begin article-title 112
Macrophage colony-stimulating factor improves cardiac function after ischemic injury by inducing vascular endothelial growth factor production and survival of cardiomyocytes.
###end article-title 112
###begin article-title 113
Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability.
###end article-title 113
###begin article-title 114
Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: Their implication in vascular endothelial growth factor gene transcription.
###end article-title 114
###begin article-title 115
Hypoxia-inducible factor 1: Regulation by hypoxic and non-hypoxic activators.
###end article-title 115
###begin article-title 116
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocyte chemoattractant protein-1 (MCP-1).
###end article-title 116
###begin article-title 117
Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: A paracrine role of tumor-associated macrophages in tumor angiogenesis.
###end article-title 117
###begin article-title 118
Effects of macrophage colony-stimulating factor (M-CSF) on protease production from monocyte, macrophage and foam cell in vitro: A possible mechanism for anti-atherosclerotic effect of M-CSF.
###end article-title 118
###begin p 119
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 119
###begin p 120
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The authors have no support or funding to report.
###end p 120

